Submitted by Armen Hareyan on Sep 7th, 2007
Carvedilol Tablets
Actavis Group has received approval from FDA to market Carvedilol tablets in the US.
Distribution of the product will commence immediately.
Carvedilol tablets, the generic equivalent of GlaxoSmithKline's Coreg tablets, will be available in 3.125, 6.25, 12.5 and 25 mg strength. Carvedilol tablets are indicated for the treatment of left ventricular dysfunction following myocardial infarction and for the management of essential hypertension.
Annual sales of carvedilol tablets in the U.S. were approximately US$1.7 billion for the twelve months ending June 2007 according to IMS Health data.
Source:
Actavis Group 